Cassava Faces Renewed Speculation Over Experimental Alzheimer’s Drug

Shares of Cassava Sciences plunged Tuesday in premarket trading after multiple Alzheimer’s researchers raised new concerns about the company’s experimental Alzheimer’s treatment, simufilam.